Chromaderm, Inc. Report issue

For profit Phase 3
Founded: Cambridge MA United States (2014)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

ruboxistaurin mesylate (10 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diabetic Nephropathies (Phase 2)

Diabetic Neuropathies (Phase 3)

Diabetic Retinopathy (Phase 3)

Edema (Phase 3)

Macular Edema (Phase 3)

Peripheral Nervous System Diseases (Phase 3)

Retinal Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 1